TEL AVIV (Reuters) – Israeli cancer immunotherapy company Compugen said on Monday that it had initial positive results from an initial ongoing study of its COM701 therapy in patients with advanced solid tumors that had exhausted all standard treatments.
COM701 was well tolerated, with no dose limiting toxicity, when administered alone and in combination with the Bristol-Myers Squibb cancer drug Opdivo (nivolumab), Compugen said.
In addition, COM701 demonstrated "encouraging signs of antitumor activity" with a high rate of disease control both in monotherapy and in combination with Opdivo – 69% and 75%, respectively, he said.
"I am very encouraged by the safety profile and the preliminary antitumor activity seen with COM701, both in monotherapy and in combination with nivolumab," said Ryan Sullivan, assistant professor of medicine at Harvard Medical School and introducing the data author on the virtual. annual meeting of the American Cancer Research Association.
The Phase 1 clinical trial was developed to assess the safety and tolerability of administering increasing doses of COM701 monotherapy, as well as combined with Opdivo.
Secondary objectives include preliminary antitumor activity in patients with selected tumor types, including non-small cell lung cancer, ovarian cancer, breast cancer, endometrial cancer and colorectal cancer.
COM701 is a humanized antibody that binds to PVRIG, a new immune checkpoint discovered computationally by Compugen.
Reporting by Tova Cohen; Editing by Steven Scheer
Our standards:The Thomson Reuters Trust principles.